Karyopharm Therapeutics

Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of drugs to improve the lives of cancer patients. Its core technology leverages nuclear export inhibition as a mechanism to treat patients with cancer and other medical conditions. The company’s vision is to pioneer a potentially new approach to treating patients with cancer and other serious diseases. Our novel approach to cancer treatment involves using SINE technology (Selective Inhibition of Nuclear Export) to target the export of specific proteins from the nucleus of cancer cells. Our primary focus is on developing new drugs that we hope will help treat patients with certain blood cancers or solid tumor malignancies.